Résumé
Objective: To systematically evaluate the efficacy and safety of Yang Yin Sheng Ji pulvis (membranae) in the treatment of recurrent oral ulcers (ROU) . Methods: All clinical studies of Yang Yin Sheng Ji pulvis (membranae) for the treatment of ROU were searched from Cochrane Library (Issue 5, 2017), Pub Med, PMC, Medline, EMBASE, CNKI, CBM, VIP and WANFANG DATA.The quality of the included studies was evaluated referring to the Cochrane Reviewer's Handbook 5. 1. 0, Meta-analysis of the total effective rate was performed using Rev Man 5. 3. 5 software, ITC software was used to compare the efficacy of Yang Yin Sheng Ji pulvis and Yang Yin Sheng Ji membranae in Meta. Results: 11 studies including 1837 patients were included. The results of Meta-analysis showed that Yang Yin Sheng Ji pulvis (membranae) for the treatment of ROU is more effective than the roultine treatment (OR = 5. 22, 95％ CI:3. 93 ～ 6. 93, P ＜ 0. 000 01), subgroup analysis showed that Yang Yin Sheng Ji pulvis and Yang Yin Sheng Ji membrane are superior to the routine treatment (OR = 5. 08, 95％ CI: 3. 63 ～ 7. 10, P ＜ 0. 000 01 and OR = 6. 67 95％ CI: 3. 82 ～ 11. 66, P ＜ 0. 000 01), respectively. Indirect comparison results showed that the total efficiency of Yang Yin Sheng Ji membrane is higher than that of Yang Yin Sheng Ji Pulvis (P = 0. 009) . No adverse reaction of Yang Yin Sheng Ji pulvis (membrane) was reported. Conclusion: Yang Yin Sheng Ji pulvis (membranae) is more effective in the treatment of ROU than the routine treatment.
Résumé
Objective To investigate the clinical efficacy of recombinant human epidermal growth factor in the treatment of recurrent oral ulcers in elderly patients.Methods 82 cases of elderly patients in our hospital in the treatment of recurrent oral ulcer were selected,41 cases in the control group,the conventional western medicine treatment,41 cases of the study group,recombinant human epidermal growth factor in treatment before and after treatment,blood determination of immune status,clinical efficacy and adverse reactions of comparison were performed at one-year follow-up.Results the effective rate of treatment group is lower than 78.05％of the effective rate of treatment group 95.12％,study group 3,6 and 12 months recurrence rate(4.88％,7.32％,7.32％)than in the control group the recurrence rate(19.51％,24.39％,29.27％),the study group after the treatment of CD3+ and CD4+/CD8+ and NK were higher than the control group,the CD8+ level is lower than the control group(P<0.05),the two groups had no serious adverse reaction.Conclusion recombinant human epidermal growth factor is effective in the treatment of oral ulcer.